NCT05278728View on ClinicalTrials.gov

Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

August 31, 2013

Study Completion Date

December 31, 2013

Conditions
Colorectal Cancer
Interventions
DRUG

Nimotuzumab

200,400,600 or 800mg weekly until progression or AEs

DRUG

Irinotecan

180mg/m2 d1, Q2w until progression or AEs or maximum 6 cycles

Trial Locations (2)

100036

Peking University, School of Oncology, Beijing Cancer Hospital & Institute, Beijing

Unknown

China People's Liberation Army (PLA)81 Hospital, Nanjing

Sponsors
All Listed Sponsors
lead

Biotech Pharmaceutical Co., Ltd.

OTHER